Combined Treatment with an Anticoagulant and a Vasodilator Prevents Steroid-Associated Osteonecrosis of Rabbit Femoral Heads by Improving Hypercoagulability

Abstract EN

Steroid-associated osteonecrosis of the femoral head remains a challenging problem in orthopedics worldwide.

One pathomechanism is ischemia of the femoral head, as a result of thrombus formation and vasoconstriction.

The present study investigates the effects of combination prevention with enoxaparin and EGb 761 on steroid-associated ONFH in rabbits.

Rabbits were randomly divided into 5 groups (control group, model group, enoxaparin group, ginkgo group, and combination group).

With the exception of the control group, the groups of rabbits were modeled with lipopolysaccharide and methylprednisolone acetate.

Starting with modeling, the enoxaparin group and ginkgo group were injected with 1 μg/kg/day enoxaparin subcutaneously and orally given 40 mg/kg/day EGb 761 for 4 weeks, respectively; the combination group received both treatments.

After modeling for 6 weeks, the hematology data indicated prolonged PT and APTT in the three prevention groups.

The micro-CT examination revealed higher bone density and better structure; histomorphometry revealed significant pathological changes.

Immunohistochemistry revealed higher expression of BMP-2 and VEGF, thus revealing better osteogenesis and angiogenesis activities.

Among the three prevention groups, the combination group had the most efficient results.

In conclusion, the combined prevention with an anticoagulant and a vasodilator has the potential to decrease the incidence of steroid-associated ONFH in rabbits.